Angina Pectoris Clinical Trial
Official title:
Phase III Confirmatory Trial to Confirm the Anti-anginal Effect of Dantonic® (T89) in Patients With Chronic Stable Angina
This phase III study is designed as a double blind, randomized, multi-nation, multi-center, placebo controlled clinical research, which aims to evaluate the safety and efficacy of Dantonic® (T89) in patients with chronic stable angina pectoris.
Dantonic® (T89) is a botanical drug consists of extracts of Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol in a capsule form. The drug is currently approved in 26 countries outside the USA for the treatment and prevention of chronic stable angina pectoris and other cardiovascular disease related conditions. This pivotal confirmative Phase III clinical trial is to confirm the efficacy and safety of the drug at 150mg and 225mg doses in the prevention and treatment of angina pectoris in patients with Chronic Stable Angina. The contribution of the main herb Danshen to, and the difference of various production batches in, the overall efficacy and safety profiles will also be explored. Patients will take a morning and an evening dose orally (every 12 hours) for 6 weeks while stop taking any long-acting nitroglycerin, ranolazine, and/or multiple beta-blockers or beta blocker(s) with calcium channel blocker during the trial. Single beta-blocker and/or on-demand short acting nitroglycerin to relief angina pectoris is allowed during the trial. After physical exams and if eligible to participation, patients will stop taking other drugs, and undergo two baseline screen Exercise Treadmill Tests (ETT) on Standard Bruce Protocol in the clinic one week before and right before starting the drug treatment. Patients will perform three more ETTs before the morning dose at the end of week 2, 4 and 6 after receiving the drug treatment. The primary efficiency endpoint is the change of symptom-limited Total Exercise Duration of the ETT at the end of the 4th week of treatment from the average of the two screening baselines compared with that of placebo treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05563701 -
Evaluation of the LVivo Image Quality Scoring (IQS)
|
||
| Recruiting |
NCT02773615 -
CT Perfusion Added to CT Angiography
|
||
| Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
| Terminated |
NCT02548611 -
Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention
|
Phase 4 | |
| Completed |
NCT02264717 -
Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease
|
N/A | |
| Completed |
NCT02440893 -
Understanding the Effect of Metformin on Corus CAD (or ASGES)
|
||
| Completed |
NCT01425359 -
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
|
Phase 4 | |
| Completed |
NCT01486030 -
Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
|
||
| Completed |
NCT01604486 -
Natural Ischaemic Preconditioning Before First Myocardial Infarction
|
N/A | |
| Completed |
NCT00811772 -
Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis
|
N/A | |
| Completed |
NCT00131183 -
Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina
|
Phase 4 | |
| Completed |
NCT00184444 -
Effect of Increased Oxygenation in the Air During Endurance Training in Stable Angina Pectoris Patients
|
N/A | |
| Completed |
NCT00235404 -
Randomized Controlled Trial of Health Care to Elderly Patients.
|
N/A | |
| Terminated |
NCT00157742 -
Comparison of SCS and PMR in Patients With Refractory Angina Pectoris
|
Phase 4 | |
| Completed |
NCT00000510 -
Platelet-Inhibitor Drug Trial in Coronary Angioplasty
|
Phase 3 | |
| Completed |
NCT00005148 -
Coronary Heart Disease Incidence, Mortality, and Risk Factor Relationships
|
N/A | |
| Not yet recruiting |
NCT03657758 -
Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO]
|
Phase 4 | |
| Completed |
NCT05050773 -
Registry Study of Medical Therapy in Patients With Angina Pectoris(GREAT)
|
||
| Completed |
NCT00093223 -
A Safety Study of ABI-007 for In-Stent Restenosis
|
Phase 2 | |
| Active, not recruiting |
NCT02508714 -
Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents
|
N/A |